Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy

[1]  S. Vino,et al.  Genetic markers as therapeutic target in rheumatoid arthritis: A game changer in clinical therapy? , 2016, Rheumatology International.

[2]  C. Allaart,et al.  Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial , 2016, The Lancet.

[3]  M. Adwan,et al.  Eular Textbook on Rheumatic Diseases , 2015, Saudi Medical Journal.

[4]  G. Burmester,et al.  Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial , 2015, Annals of the rheumatic diseases.

[5]  Hong Duan,et al.  Identification of genes associated with methotrexate resistance in methotrexate-resistant osteosarcoma cell lines , 2015, Journal of Orthopaedic Surgery and Research.

[6]  Stephen Brown,et al.  Methotrexate Is a JAK/STAT Pathway Inhibitor , 2015, PloS one.

[7]  A. Suzuki,et al.  From genetics to functional insights into rheumatoid arthritis. , 2015, Clinical and experimental rheumatology.

[8]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[9]  H. Canhão,et al.  Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity? , 2014, Immunologic Research.

[10]  U. Müller-Ladner,et al.  G protein-coupled receptors in rheumatology , 2014, Nature Reviews Rheumatology.

[11]  Helena Canhão,et al.  FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries , 2014 .

[12]  R. Giacomelli,et al.  Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. , 2014, Clinical therapeutics.

[13]  Désirée van der Heijde,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update , 2013, Annals of the rheumatic diseases.

[14]  J. Kremer,et al.  Tocilizumab as monotherapy or in combination with nonbiologic disease‐modifying antirheumatic drugs: Twenty‐four–week results of an open‐label, clinical practice study , 2013, Arthritis care & research.

[15]  M. Dougados,et al.  Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) , 2012, Annals of the rheumatic diseases.

[16]  A. Kavanaugh,et al.  Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study , 2011, Annals of the rheumatic diseases.

[17]  Ricardo Blanco,et al.  Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. , 2011, Arthritis and rheumatism.

[18]  L. Moreland,et al.  Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy , 2010, Drug design, development and therapy.

[19]  G. Tobón,et al.  The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. , 2010, Journal of autoimmunity.

[20]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[21]  Matthew D. Young,et al.  Gene ontology analysis for RNA-seq: accounting for selection bias , 2010, Genome Biology.

[22]  K. Liao,et al.  Environmental influences on risk for rheumatoid arthritis , 2009, Current opinion in rheumatology.

[23]  M. Genovese,et al.  Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study , 2009, Annals of the rheumatic diseases.

[24]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[25]  D. M. van der Heijde,et al.  Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research , 2008, Annals of the rheumatic diseases.

[26]  Kazuhiko Yamamoto,et al.  Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy , 2008, Modern rheumatology.

[27]  M. Genovese,et al.  Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. , 2008, Arthritis and rheumatism.

[28]  J. Kremer,et al.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial , 2008, Annals of the rheumatic diseases.

[29]  Zhenjun Hu,et al.  Visant: an Integrative Framework for Networks in Systems Biology , 2008 .

[30]  J. Smolen,et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.

[31]  T. Huizinga,et al.  Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. , 2007, Rheumatology.

[32]  S. Geraci,et al.  Rheumatoid arthritis: diagnosis and management. , 2007, The American journal of medicine.

[33]  E. Keystone,et al.  Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. , 2007, Arthritis and rheumatism.

[34]  D. M. van der Heijde,et al.  Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab , 2007, Annals of the rheumatic diseases.

[35]  P. Emery,et al.  Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. , 2006, Arthritis and rheumatism.

[36]  Malcolm D. Smith,et al.  The Jak-STAT pathway in rheumatoid arthritis. , 2005, The Journal of rheumatology.

[37]  Roy Parker,et al.  Nonsense-mediated mRNA decay: terminating erroneous gene expression. , 2004, Current opinion in cell biology.

[38]  Zhenjun Hu,et al.  VisANT: an online visualization and analysis tool for biological interaction data , 2004, BMC Bioinformatics.

[39]  F. Breedveld,et al.  HLA class II association with rheumatoid arthritis: facts and interpretations. , 2000, Human immunology.

[40]  M. Picot,et al.  Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. , 1997, British journal of rheumatology.

[41]  J. Kremer,et al.  Methotrexate for Rheumatoid Arthritis , 1994 .

[42]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[43]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.